Stephan Mielke

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster, Michael Bishop, Constantine S. Tam et al. · New England Journal of Medicine · 2018 · 3.9K citations · Full text

International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium

Andrew C. Harris, Rachel Young, Steven M. Devine et al. · Biology of Blood and Marrow Transplantation · 2015 · 882 citations · Full text

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

Manali Kamdar, Scott R. Solomon, Jon Arnason et al. · The Lancet · 2022 · 704 citations

Second-line Treatment, Salvage Chemotherapy, Interim Analysis +9

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

Robert Zeiser, Andreas Burchert, Claudia Lengerke et al. · Leukemia · 2015 · 535 citations · Full text

Transplantation, Stem Cell Transplantation, Transplantation Medicine +9

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

Stephen J. Schuster, Constantine S. Tam, Peter Borchmann et al. · The Lancet Oncology · 2021 · 528 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +8